Form 4: Entrada Therapeutics' Chief Scientific Officer Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Natarajan Sethuraman, Chief Scientific Officer of Entrada Therapeutics, sold a total of 1,238 shares of common stock on July 12 and July 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Natarajan Sethuraman, the Chief Scientific Officer of Entrada Therapeutics, Inc. (TRDA), reported changes in beneficial ownership of the company's common stock.
- On July 12, 2024, Sethuraman sold 600 shares at a price of $18 per share.
- On July 15, 2024, Sethuraman sold 638 shares at a price of $18 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these transactions, Sethuraman directly owns 188,814 shares of Entrada Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock sales by an insider. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.
Stakeholder Impact
- Shareholders may interpret insider sales as a lack of confidence in the company, although sales under a 10b5-1 plan are often pre-scheduled and may not reflect the insider's current outlook.
Key Dates
| Date | Description |
|---|---|
| 2023-12-14 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-07-12 | Date of first transaction: Sale of 600 shares |
| 2024-07-15 | Date of second transaction: Sale of 638 shares |
| 2024-07-16 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.